Stockscreener 앱 받기
11.00
0.50%
-0.055
시간 외 거래:
11.00
전일 마감가:
$11.05
열려 있는:
$11.02
하루 거래량:
28,078
Relative Volume:
0.56
시가총액:
$98.64M
수익:
-
순이익/손실:
$-39.72M
주가수익비율:
-0.5993
EPS:
-18.3554
순현금흐름:
$-28.18M
1주 성능:
-1.35%
1개월 성능:
+0.36%
6개월 성능:
+12.62%
1년 성능:
-23.48%
1일 변동 폭
$10.88
$11.49
1주일 범위
$10.88
$11.50
52주 변동 폭
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
11.00 | 99.14M | 0 | -39.72M | -28.18M | -18.36 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
PMN Price Today: ProMIS Neurosciences Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Director Kirwin’s entity buys 4,000 ProMIS (PMN) shares at $11.33 - Stock Titan
PMN ProMIS Neurosciences Inc. Common Shares (ON) posts wider than expected Q4 2025 loss but still notches small share price gain today.Equity Raise - UBND thành phố Hải Phòng
ProMIS (PMN) Stock: Is It Overpriced in Market (Drifts Lower) 2026-04-18Fast Rising Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CEO Neil Warma to outline Alzheimer’s trial timeline at Apr. 21 event - Stock Titan
Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn
What events could move ProMIS (PMN) Stock next | Price at $12.95, Up 2.78%Top Analyst Picks - Newser
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan
Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN
ProMIS Neurosciences | DEFA14A: Others - Moomoo
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
How does currency impact ProMIS (PMN) Stock | Price at $10.88, Down 0.73%Community Watchlist - Newser
ProMIS Neurosciences Shares Plunge Amid Critical Clinical Trial Phase - AD HOC NEWS
Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan
Is ProMIS (PMN) Stock Overpriced Now | Price at $11.05, Down 11.67%Industry Analysis - Newser
PMN Technical Analysis & Stock Price Forecast - Intellectia AI
Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
PMN Faces Selling Pressure: Technical Levels to Watch - Newser
Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn
Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView
[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan
ProMIS Neurosciences | EFFECT: Others - Moomoo
Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart
ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan
ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView
Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView
Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - ChartMill
Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World
How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan
Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan
Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan
ProMIS Neurosciences to Present Data on ALS & Parkinsons - GlobeNewswire
ALS, Parkinson’s vaccine data to debut at leading AD/PD 2026 meeting - Stock Titan
ProMIS Neurosciences, Inc. (PMN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Abg V Siv X Ltd Net Worth (2026) - GuruFocus
Abg V Siv Ix Ltd Net Worth (2026) - GuruFocus
Sentiment Recap: Can ProMIS Neurosciences Inc. continue delivering strong returns2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):